UK Markets open in 5 hrs 3 mins

DBV Technologies S.A. (DBVT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.6400-0.0100 (-0.61%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.6500
Open1.6727
Bid1.5300 x 900
Ask1.6500 x 1300
Day's range1.6200 - 1.6800
52-week range1.3510 - 7.3800
Volume49,089
Avg. volume694,670
Market cap185.297M
Beta (5Y monthly)2.21
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Globe Newswire

    Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2021

    Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights12/31/202155,095,762 Total gross of voting rights: 55,095,762 Total net* of voting rights: 54,942,131 * Total net = total number of voting rights attached to shares – shares wi

  • Globe Newswire

    DBV Technologies to Present at the H.C. Wainwright BioConnect 2022 Conference

    Montrouge, France, January 7, 2022 DBV Technologies to Present at the H.C. Wainwright BioConnect 2022 Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright BioConnect 2022 Conference. The fireside chat will be available for on-demand viewing starting Monday, January 10, 2022, at 7:00am ET. A webc

  • Globe Newswire

    DBV Technologies Provides Update on Investigational Viaskin™ Peanut

    Montrouge, France, December 20, 2021 DBV Technologies Provides Update on Investigational Viaskin™ Peanut DBV Technologies S.A. (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced plans to initiate a new, pivotal Phase 3 clinical study for a modified Viaskin™ Peanut patch in children in the intended patient population. The Company also issued an update on the Marketing Authorization Application for Viaskin Peanut with the E